

PDR®  
**54**  
EDITION  
2000

# PHYSICIANS' DESK REFERENCE®

**Senior Vice President, Directory Services:** Paul Walsh

**Director of Product Management:** Mark A. Friedman

**Associate Product Manager:** Bill Shaughnessy

**Senior Business Manager:** Mark S. Ritchin

**Financial Analyst:** Wayne M. Soltis

**Director of Sales:** Dikran N. Barsamian

**National Sales Manager, Pharmaceutical Sales:** Anthony Sorce

**National Account Manager:** Don Bruccoleri

**Senior Account Manager:** Frank Karkowsky

**Account Managers:**

Marion Gray, RPh

Lawrence C. Keary

Jeffrey F. Pfohl

Suzanne E. Yarrow, RN

**Electronic Sales Account Manager:** Stephen M. Silverberg

**National Sales Manager, Medical Economics Trade Sales:** Bill Gaffney

**Director of Direct Marketing:** Michael Bennett

**List and Production Manager:** Lorraine M. Loening

**Senior Marketing Analyst:** Dina A. Maeder

**Director, New Business Development and**

**Professional Support Services:** Mukesh Mehta, RPh

**Manager, Drug Information Services:** Thomas Fleming, RPh

**Drug Information Specialist:** Maria Deutsch, MS, RPh, CDE

**Editor, Directory Services:** David W. Sifton

**Senior Associate Editor:** Lori Murray

**Director of Production:** Carrie Williams

**Manager of Production:** Kimberly H. Vivas

**Senior Production Coordinator:** Amy B. Brooks

**Production Coordinators:** Gianna Caradonna, Maria Volpati

**Data Manager:** Jeffrey D. Schaefer

**Senior Format Editor:** Gregory J. Westley

**Index Editors:** Johanna M. Mazur, Robert N. Woerner

**Art Associate:** Joan K. Akerlind

**Senior Digital Imaging Coordinator:** Shawn W. Cahill

**Digital Imaging Coordinator:** Frank J. McElroy, III

**Electronic Publishing Designer:** Livio Udina

**Fulfillment Manager:** Stephanie DeNardi



Copyright © 2000 and published by Medical Economics Company, Inc. at Montvale, NJ 07645-1742. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, resold, redistributed, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without the prior written permission of the publisher. PHYSICIANS' DESK REFERENCE®, PDR®, PDR For Ophthalmology®, Pocket PDR®, and The PDR® Family Guide to Prescription Drugs® are registered trademarks used herein under license. PDR For Nonprescription Drugs and Dietary Supplements™, PDR Companion Guide™, PDR® for Herbal Medicines™, PDR® Medical Dictionary™, PDR® Nurse's Drug Handbook™, PDR® Nurse's Dictionary™, The PDR® Family Guide Encyclopedia of Medical Care™, The PDR® Family Guide to Natural Medicines and Healing Therapies™, The PDR® Family Guide to Common Ailments™, The PDR® Family Guide to Over-the-Counter Drugs™, and PDR® Electronic Library™ are trademarks used herein under license.

**Officers of Medical Economics Company:** *President and Chief Executive Officer:* Curtis B. Allen; *Vice President, New Media:* L. Suzanne BeDell; *Vice President, Corporate Human Resources:* Pamela M. Bilash; *Vice President and Chief Information Officer:* Steven M. Bressler; *Chief Financial Officer:* Christopher Caridi; *Vice President and Controller:* Barry Gray; *Vice President, New Business Planning:* Linda G. Hope; *Vice President, Business Integration:* David A. Pitter; *Vice President, Finance:* Donna Santarpia; *Senior Vice President, Directory Services:* Paul Walsh; *Senior Vice President, Operations:* John R. Ware; *Senior Vice President, Internet Strategies:* Raymond Zoeller



Printed on recycled paper

ISBN: 1-56363-330-2

**DOCKET  
ALARM**

Find authenticated court documents without watermarks at [docketalarm.com](http://docketalarm.com).



**NAPHCON® A**  
**Eye Drops**  
**Relieves Itching & Redness**  
**EYE ALLERGY RELIEF**

Temporary relief of the minor eye symptoms of itching and redness caused by ragweed, pollen, grass, animal hair, and dander.

**DESCRIPTION**

**Active:** Pheniramine Maleate 0.3%, Naphazoline Hydrochloride 0.025%. **Preservative:** Benzalkonium Chloride 0.01%. **Inactives:** Sodium Chloride, Boric Acid, Sodium Borate, Edetate Disodium 0.01%, Sodium Hydroxide and/or Hydrochloric Acid (to adjust pH), Purified Water. The sterile ophthalmic solution has a pH of about 6 and a tonicity of about 270 mOsm/Kg.

**DIRECTIONS**

Instill 1 or 2 drops in the affected eye(s) up to 4 times daily.

**WARNINGS**

To avoid contamination, do not touch tip of container to any surface. Replace cap after using.  
If solution changes color or becomes cloudy, do not use.  
If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens, or persists for more than 72 hours, discontinue use and consult a physician. Overuse of this product may produce increased redness of the eye.  
If you are sensitive to any ingredient in this product, do not use. Do not use this product if you have heart disease, high blood pressure, difficulty in urination due to enlargement of the prostate gland or narrow angle glaucoma unless directed by a physician.  
Accidental oral ingestion in infants and children may lead to coma and marked reduction in body temperature. Before using in children under 6 years of age, consult your physician.  
Keep this and all drugs out of reach of children. In case of accidental ingestion, seek professional assistance or contact a Poison Control Center immediately.  
Remove contact lenses before using.  
Store at 36°-80°F (2°-27°C).  
Protect from light.  
Use before the expiration date marked on the carton or bottle.  
Keep this and all drugs out of reach of children.

**PATANOL®**  
**(olopatadine hydrochloride ophthalmic solution) 0.1%**

**DESCRIPTION**

PATANOL® (olopatadine hydrochloride ophthalmic solution) 0.1% is a sterile ophthalmic solution containing olopatadine, a relatively selective H<sub>1</sub>-receptor antagonist and inhibitor of histamine release from the mast cell for topical administration to the eyes. Olopatadine hydrochloride is a white, crystalline, water-soluble powder with a molecular weight of 373.88.

**Chemical Name:** 11-(Z)-3-(Dimethylamino)propylidene-6-11-dihydrodibenz[b,e] oxepin-2-acetic acid hydrochloride  
Each mL of PATANOL contains: **Active:** 1.11 mg olopatadine hydrochloride equivalent to 1 mg olopatadine. **Preservative:** benzalkonium chloride 0.01%. **Inactives:** dibasic sodium phosphate; sodium chloride; hydrochloric acid/sodium hydroxide (adjust pH); and purified water.  
It has a pH of approximately 7 and an osmolality of approximately 300 mOsm/kg.

**CLINICAL PHARMACOLOGY**

Olopatadine is an inhibitor of the release of histamine from the mast cell and a relatively selective histamine H<sub>1</sub>-antagonist that inhibits the *in vivo* and *in vitro* type 1 immediate hypersensitivity reaction. Olopatadine is devoid of effects on alpha-adrenergic, dopamine, muscarinic type 1 and 2, and serotonin receptors. Following topical ocular administration in man, olopatadine was shown to have low systemic exposure. Two studies in normal volunteers (totaling 24 subjects) dosed bilaterally with olopatadine 0.15% ophthalmic solution once every 12 hours for 2 weeks demonstrated plasma concentrations to be generally below the quantitation limit of the assay (<0.5 ng/mL). Samples in which olopatadine was quantifiable were typically found within 2 hours of dosing and ranged from 0.5 to 1.3 ng/mL. The half-life in plasma was approximately 3 hours, and elimination was predominantly through renal excretion. Approximately 60-70% of the dose was recovered in the urine as parent drug. Two metabolites, the mono-desmethyl and the N-oxide, were detected at low concentrations in the urine. Results from conjunctival antigen challenge studies demonstrated that PATANOL, when subjects were challenged with antigen both initially and up to 8 hours after dosing, was significantly more effective than its vehicle in preventing ocular itching associated with allergic conjunctivitis.

**INDICATIONS AND USAGE**

PATANOL (olopatadine hydrochloride ophthalmic solution)

**WARNINGS**

PATANOL® is for topical use only and not for injection or oral use.

**PRECAUTIONS**

**Information for Patients:** To prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.  
Patients should be advised not to wear a contact lens if their eye is red. PATANOL® should not be used to treat contact lens related irritation. The preservative in PATANOL, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red, should be instructed to wait at least ten minutes after instilling PATANOL before they insert their contact lenses.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** Olopatadine administered orally was not carcinogenic in mice and rats in doses up to 500 mg/kg/day and 200 mg/kg/day, respectively. Based on a 40 µl drop size, these doses were 78,125 and 31,250 times higher than the maximum recommended ocular human dose (MROHD). No mutagenic potential was observed when olopatadine was tested in an *in vitro* bacterial reverse mutation (Ames) test, an *in vitro* mammalian chromosome aberration assay or an *in vivo* mouse micronucleus test. Olopatadine administered to male and female rats at oral doses of 62,500 times MROHD level resulted in a slight decrease in the fertility index and reduced implantation rate; no effects on reproductive function were observed at doses of 7,800 times the maximum recommended ocular human use level.

**Pregnancy: Pregnancy Category C.** Olopatadine was found not to be teratogenic in rats and rabbits. However, rats treated at 600 mg/kg/day, or 93,750 times the MROHD and rabbits treated at 400 mg/kg/day, or 62,500 times the MROHD, during organogenesis showed a decrease in live fetuses. There are, however, no adequate and well controlled studies in pregnant women. Because animal studies are not always predictive of human responses, this drug should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.

**Nursing Mothers:** Olopatadine has been identified in the milk of nursing rats following oral administration. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when PATANOL® is administered to a nursing mother.

**Pediatric Use:** Safety and effectiveness in pediatric patients below the age of 3 years have not been established.

**ADVERSE REACTIONS**

Headaches were reported at an incidence of 7%. The following adverse experiences were reported in less than 5% of patients: Asthenia, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, keratitis, lid edema, pharyngitis, pruritus, rhinitis, sinusitis, and taste perversion. Some of these events were similar to the underlying disease being studied.

**DOSE AND ADMINISTRATION**

The recommended dose is one to two drops in each affected eye two times per day at an interval of 6 to 8 hours.

**HOW SUPPLIED**

PATANOL® (olopatadine hydrochloride ophthalmic solution) 0.1% is supplied as follows: 5 mL in plastic DROP-TAINER® dispenser.

5 mL: NDC 0065-0271-05  
**Storage:** Store at 39°F to 86°F (4°C to 30°C).  
U.S. Patents Nos. 4,871,865; 4,923,892; 5,116,863; 5,641,805.

**Rx Only.**

**TEARS NATURALE® II**

**Lubricant Eye Drops**  
**TEARS NATURALE FREE®**  
**Lubricant Eye Drops**

**DESCRIPTION**

TEARS NATURALE® II is the only lubricant eye drop preserved with safe, nonsensitizing POLYQUAD 0.001%. *In vitro* studies have shown that POLYQUAD substantially avoids the damaging effects of epithelial cell toxicity possible with other tear substitute preservatives and allows epithelial cell growth. POLYQUAD has been shown to be 99% reaction-free in normal subjects and 97% reaction-free in subjects known to be preservative sensitive. TEARS NATURALE FREE is a preservative-free version of TEARS NATURALE II.

With their unique mucin like polymeric formulation, and with their natural pH, low viscosity, and isotonicity, TEARS NATURALE II and TEARS NATURALE FREE provide dry eye patients with comfort and prompt relief of dry eye symptoms.  
Sterile. For Topical Eye Use Only

**active:** Sodium Borate, Potassium Chloride, Sodium Chloride, Purified Water. May contain Hydrochloric Acid and/or Sodium Hydroxide to adjust pH.

**TEARS NATURALE FREE:** Each mL contains:

**Active:** DUASORB®, a water soluble polymeric system containing Dextran 70 0.1% and Hydroxypropyl Methylcellulose 2910 0.3%.

**Inactives:** Sodium Borate, Potassium Chloride, Sodium Chloride, Purified Water. May contain Hydrochloric Acid and/or Sodium Hydroxide to adjust pH.

**INDICATIONS**

For the temporary relief of burning and irritation due to dryness of the eye and for use as a protectant against further irritation. For the temporary relief of discomfort due to minor irritations of the eye or to exposure to wind or sun.

**WARNINGS**

If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours, discontinue use and consult a doctor.

If solution changes color or becomes cloudy, do not use.

To avoid contamination, do not touch tip of container to any surface. Replace cap after using. Keep this and all drugs out of the reach of children. In case of accidental ingestion, seek professional assistance or contact a Poison Control Center immediately.

**DIRECTIONS**

**TEARS NATURALE® II:** Instill 1 or 2 drops in the affected eye(s) as needed. **TEARS NATURALE FREE:** Make sure container is intact before use. To open, completely TWIST off tab. DO NOT pull off. Instill 1 or 2 drops in the affected eye(s) as needed. To close, align cap at right angle (90°) to vial and firmly press down. Improved vial design reduces chance of leakage. **DISCARD CONTAINER 12 HOURS AFTER OPENING.**

**HOW SUPPLIED**

**TEARS NATURALE II** Lubricant Eye Drops are supplied in 15 mL and 30 mL plastic DROP-TAINER® bottles.

15 mL NDC 0065-0418-15

30 mL NDC 0065-0418-30

**TEARS NATURALE FREE** Lubricant Eye Drops are supplied in boxes of 35 0.03 fl. oz. re-closable vials.

NDC 0065-0416-32

**STORAGE:** Store at room temperature.

**TOBRADEX®**  
**(tobramycin and dexamethasone**  
**ophthalmic suspension and ointment)**  
**Sterile**

**DESCRIPTION**

TOBRADEX® (tobramycin and dexamethasone ophthalmic suspension and ointment) are sterile, multiple dose antibiotic and steroid combinations for topical ophthalmic use.

**Tobramycin**

**Chemical name:**

*O*-3-Amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 4)-*O*-[2,6-diamino-2,3,6-trideoxy- $\alpha$ -D-ribo-hexopyranosyl-(1 $\rightarrow$ 6)]-1,2-deoxy-L-streptamine

**Dexamethasone**

**Chemical Name:**

9-Fluoro-11 $\beta$ ,17,21-trihydroxy-16 $\alpha$ -methylpregna-1,4-diene-3,20-dione

Each mL of TOBRADEX® Suspension contains: **Active:** Tobramycin 0.3% (3 mg) and Dexamethasone 0.1% (1 mg). **Preservative:** Benzalkonium Chloride 0.01%. **Inactives:** Tyloxapol, Edetate Disodium, Sodium Chloride, Hydroxyethyl Cellulose, Sodium Sulfate, Sulfuric Acid and/or Sodium Hydroxide (to adjust pH) and Purified Water.

Each gram of TOBRADEX® Ointment contains: **Actives:** Tobramycin 0.3% (3 mg) and Dexamethasone 0.1% (1 mg). **Preservative:** Chlorobutanol 0.5%. **Inactives:** Mineral Oil and White Petrolatum.

**CLINICAL PHARMACOLOGY**

Corticoids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Since corticoids may inhibit the body's defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant. Dexamethasone is a potent corticoid.

The antibiotic component in the combination (tobramycin) is included to provide action against susceptible organisms. *In vitro* studies have demonstrated that tobramycin is active against susceptible strains of the following microorganisms:

Staphylococci, including *S. aureus* and *S. epidermidis* (coagulase-positive and coagulase-negative), including penicillin-resistant strains.

Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some *Streptococcus*



**NAPHCON® A**  
**Eye Drops**  
**Relieves Itching & Redness**  
**EYE ALLERGY RELIEF**

Temporary relief of the minor eye symptoms of itching and redness caused by ragweed, pollen, grass, animal hair, and dander.

**DESCRIPTION**

**Active:** Pheniramine Maleate 0.3%, Naphazoline Hydrochloride 0.025%. **Preservative:** Benzalkonium Chloride 0.01%. **Inactive:** Sodium Chloride, Boric Acid, Sodium Borate, Edetate Disodium 0.01%, Sodium Hydroxide and/or Hydrochloric Acid (to adjust pH), Purified Water. The sterile ophthalmic solution has a pH of about 6 and a tonicity of about 270 mOsm/Kg.

**DIRECTIONS**

Instill 1 or 2 drops in the affected eye(s) up to 4 times daily.

**WARNINGS**

To avoid contamination, do not touch tip of container to any surface. Replace cap after using.  
If solution changes color or becomes cloudy, do not use.  
If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens, or persists for more than 72 hours, discontinue use and consult a physician. Overuse of this product may produce increased redness of the eye.  
If you are sensitive to any ingredient in this product, do not use. Do not use this product if you have heart disease, high blood pressure, difficulty in urination due to enlargement of the prostate gland or narrow angle glaucoma unless directed by a physician.  
Accidental oral ingestion in infants and children may lead to coma and marked reduction in body temperature. Before using in children under 6 years of age, consult your physician.  
Keep this and all drugs out of reach of children. In case of accidental ingestion, seek professional assistance or contact a Poison Control Center immediately.  
Remove contact lenses before using.  
Store at 36°-80°F (2°-27°C).  
Protect from light.  
Use before the expiration date marked on the carton or bottle.  
Keep this and all drugs out of reach of children.

**PATANOL®**  
**(olopatadine hydrochloride ophthalmic solution) 0.1%**

**DESCRIPTION**

PATANOL® (olopatadine hydrochloride ophthalmic solution) 0.1% is a sterile ophthalmic solution containing olopatadine, a relatively selective H<sub>1</sub>-receptor antagonist and inhibitor of histamine release from the mast cell for topical administration to the eyes. Olopatadine hydrochloride is a white, crystalline, water-soluble powder with a molecular weight of 373.88.

**Chemical Name:** 11-(Z)-3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride. Each mL of PATANOL contains: **Active:** 1.11 mg olopatadine hydrochloride equivalent to 1 mg olopatadine; **Preservative:** benzalkonium chloride 0.01%. **Inactives:** dibasic sodium phosphate; sodium chloride; hydrochloric acid/sodium hydroxide (adjust pH); and purified water.  
It has a pH of approximately 7 and an osmolality of approximately 300 mOsm/kg.

**CLINICAL PHARMACOLOGY**

Olopatadine is an inhibitor of the release of histamine from the mast cell and a relatively selective histamine H<sub>1</sub>-antagonist that inhibits the *in vivo* and *in vitro* type 1 immediate hypersensitivity reaction. Olopatadine is devoid of effects on alpha-adrenergic, dopamine, muscarinic type 1 and 2, and serotonin receptors. Following topical ocular administration in man, olopatadine was shown to have low systemic exposure. Two studies in normal volunteers (totaling 24 subjects) dosed bilaterally with olopatadine 0.15% ophthalmic solution once every 12 hours for 2 weeks demonstrated plasma concentrations to be generally below the quantitation limit of the assay (<0.5 ng/mL). Samples in which olopatadine was quantifiable were typically found within 2 hours of dosing and ranged from 0.5 to 1.3 ng/mL. The half-life in plasma was approximately 3 hours, and elimination was predominantly through renal excretion. Approximately 60-70% of the dose was recovered in the urine as parent drug. Two metabolites, the mono-desmethyl and the N-oxide, were detected at low concentrations in the urine. Results from conjunctival antigen challenge studies demonstrated that PATANOL, when subjects were challenged with antigen both initially and up to 8 hours after dosing, was significantly more effective than its vehicle in preventing ocular itching associated with allergic conjunctivitis.

**INDICATIONS AND USAGE**

PATANOL (olopatadine hydrochloride ophthalmic solution)

**WARNINGS**

PATANOL® is for topical use only and not for injection or oral use.

**PRECAUTIONS**

**Information for Patients:** To prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.  
Patients should be advised not to wear a contact lens if their eye is red. PATANOL® should not be used to treat contact lens related irritation. The preservative in PATANOL, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red, should be instructed to wait at least ten minutes after instilling PATANOL before they insert their contact lenses.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** Olopatadine administered orally was not carcinogenic in mice and rats in doses up to 500 mg/kg/day and 200 mg/kg/day, respectively. Based on a 40 µl drop size, these doses were 78,125 and 31,250 times higher than the maximum recommended ocular human dose (MROHD). No mutagenic potential was observed when olopatadine was tested in an *in vitro* bacterial reverse mutation (Ames) test, an *in vitro* mammalian chromosome aberration assay or an *in vivo* mouse micronucleus test. Olopatadine administered to male and female rats at oral doses of 62,500 times MROHD level resulted in a slight decrease in the fertility index and reduced implantation rate; no effects on reproductive function were observed at doses of 7,800 times the maximum recommended ocular human dose level.

**Pregnancy: Pregnancy Category C.** Olopatadine was found not to be teratogenic in rats and rabbits. However, rats treated at 600 mg/kg/day, or 93,750 times the MROHD and rabbits treated at 400 mg/kg/day, or 62,500 times the MROHD, during organogenesis showed a decrease in live fetuses. There are, however, no adequate and well controlled studies in pregnant women. Because animal studies are not always predictive of human responses, this drug should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.

**Nursing Mothers:** Olopatadine has been identified in the milk of nursing rats following oral administration. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when PATANOL® is administered to a nursing mother.

**Pediatric Use:** Safety and effectiveness in pediatric patients below the age of 3 years have not been established.

**ADVERSE REACTIONS**

Headaches were reported at an incidence of 7%. The following adverse experiences were reported in less than 5% of patients: Asthenia, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, keratitis, lid edema, pharyngitis, pruritus, rhinitis, sinusitis, and taste perversion. Some of these events were similar to the underlying disease being studied.

**DOSAGE AND ADMINISTRATION**

The recommended dose is one to two drops in each affected eye two times per day at an interval of 6 to 8 hours.

**HOW SUPPLIED**

PATANOL® (olopatadine hydrochloride ophthalmic solution) 0.1% is supplied as follows: 5 mL in plastic DROP-TAINER® dispenser.

5 mL: NDC 0065-0271-05  
**Storage:** Store at 39°F to 86°F (4°C to 30°C).  
U.S. Patents Nos. 4,871,865; 4,923,892; 5,116,863; 5,641,805.

**Rx Only.**

**TEARS NATURALE® II**  
**Lubricant Eye Drops**  
**TEARS NATURALE FREE®**  
**Lubricant Eye Drops**

**DESCRIPTION**

TEARS NATURALE® II is the only lubricant eye drop preserved with safe, nonsensitizing POLYQUAD 0.001%. *In vitro* studies have shown that POLYQUAD substantially avoids the damaging effects of epithelial cell toxicity possible with other tear substitute preservatives and allows epithelial cell growth. POLYQUAD has been shown to be 99% reaction-free in normal subjects and 97% reaction-free in subjects known to be preservative sensitive. TEARS NATURALE FREE is a preservative-free version of TEARS NATURALE II.  
With their unique mucin like polymeric formulation, and with their natural pH, low viscosity, and isotonicity, TEARS NATURALE II and TEARS NATURALE FREE provide dry eye patients with comfort and prompt relief of dry eye symptoms.  
Sterile For Topical Eye Use Only

**active:** Sodium Borate, Potassium Chloride, Sodium Chloride, Purified Water. May contain Hydrochloric Acid and/or Sodium Hydroxide to adjust pH.

**TEARS NATURALE FREE:** Each mL contains:  
**Active:** DUASORB®, a water soluble polymeric system containing Dextran 70 0.1% and Hydroxypropyl Methylcellulose 2910 0.3%.

**Inactives:** Sodium Borate, Potassium Chloride, Sodium Chloride, Purified Water. May contain Hydrochloric Acid and/or Sodium Hydroxide to adjust pH.

**INDICATIONS**

For the temporary relief of burning and irritation due to dryness of the eye and for use as a protectant against further irritation. For the temporary relief of discomfort due to minor irritations of the eye or to exposure to wind or sun.

**WARNINGS**

If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours, discontinue use and consult a doctor.

If solution changes color or becomes cloudy, do not use.  
To avoid contamination, do not touch tip of container to any surface. Replace cap after using. Keep this and all drugs out of the reach of children. In case of accidental ingestion, seek professional assistance or contact a Poison Control Center immediately.

**DIRECTIONS**

**TEARS NATURALE® II:** Instill 1 or 2 drops in the affected eye(s) as needed. **TEARS NATURALE FREE:** Make sure container is intact before use. To open, completely TWIST off tab. DO NOT pull off. Instill 1 or 2 drops in the affected eye(s) as needed. To close, align cap at right angle (90°) to vial and firmly press down. Improved vial design reduces chance of leakage. **DISCARD CONTAINER 12 HOURS AFTER OPENING.**

**HOW SUPPLIED**

TEARS NATURALE II Lubricant Eye Drops are supplied in 15 mL and 30 mL plastic DROP-TAINER® bottles.

15 mL NDC 0065-0418-15  
30 mL NDC 0065-0418-30  
TEARS NATURALE FREE Lubricant Eye Drops are supplied in boxes of 35 0.03 fl. oz. re-closable vials.  
NDC 0065-0416-32

**STORAGE:** Store at room temperature.

**TOBRADEX®**  
**(tobramycin and dexamethasone ophthalmic suspension and ointment)**  
**Sterile**

**DESCRIPTION**

TOBRADEX® (tobramycin and dexamethasone ophthalmic suspension and ointment) are sterile, multiple dose antibiotic and steroid combinations for topical ophthalmic use.

**Tobramycin**  
Chemical name:  
O-3-Amino-3-deoxy-α-D-glucopyranosyl-(1→4)-O-[2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl-(1→6)]-2-deoxy-L-streptamine  
**Dexamethasone**  
Chemical Name:  
9-Fluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione

Each mL of TOBRADEX® Suspension contains: **Active:** Tobramycin 0.3% (3 mg) and Dexamethasone 0.1% (1 mg). **Preservative:** Benzalkonium Chloride 0.01%. **Inactives:** Tyloxapol, Edetate Disodium, Sodium Chloride, Hydroxyethyl Cellulose, Sodium Sulfate, Sulfuric Acid and/or Sodium Hydroxide (to adjust pH) and Purified Water.  
Each gram of TOBRADEX® Ointment contains: **Actives:** Tobramycin 0.3% (3 mg) and Dexamethasone 0.1% (1 mg). **Preservative:** Chlorobutanol 0.5%. **Inactives:** Mineral Oil and White Petrolatum.

**CLINICAL PHARMACOLOGY**

Corticoids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Since corticoids may inhibit the body's defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant. Dexamethasone is a potent corticoid.  
The antibiotic component in the combination (tobramycin) is included to provide action against susceptible organisms. *In vitro* studies have demonstrated that tobramycin is active against susceptible strains of the following microorganisms:  
Staphylococci, including *S. aureus* and *S. epidermidis* (coagulase-positive and coagulase-negative), including penicillin-resistant strains.  
Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some *Streptococcus*